Список литературы

Поставить закладку

Isidori A. et al. Iron toxicity - Its effect on the bone marrow. // Blood Rev. England, 2018. Vol. 32, № 6. P. 473–479.
Marsh J.C.W., Kulasekararaj A.G. Management of the refractory aplastic anemia patient: what are the options? // Blood. 2013. Vol. 122, № 22. P. 3561–3567.
Frickhofen N. et al. Antithymocyte globulin with or without cyclosporin A: 11-Year follow-up of a randomized trial comparing treatments of aplastic anemia // Blood. 2003. Vol. 101, № 4. P. 1236–1242.
Kulasekararaj A.G. et al. Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome // Blood. 2014. Vol. 124, № 17. P. 2698–2704.
Afable M.G., Tiu R. V, Maciejewski J.P. Clonal Evolution in Aplastic Anemia // Hematology. 2011. № 1. P. 90–95.
Pu J.J. et al. Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia // Eur. J. Haematol. 2011. Vol. 87, № 1. P. 37–45.
Socié G. et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors // Lancet. 1996. Vol. 348, № 9027. P. 573–577.
Kulagin A. et al. Prognostic value of paroxysmal nocturnal haemoglobinuria clone presence in aplastic anaemia patients treated with combined immunosuppression: Results of two-centre prospective study // Br. J. Haematol. 2014. Vol. 164, № 4. P. 546–554.
Li Y. et al. Long-term follow-up of clonal evolutions in 802 aplastic anemia patients: A single-center experience // Ann. Hematol. 2011. Vol. 90, № 5. P. 529–537.
Кулагин А.Д., Лисуков И.А., Птушкин В.В., Шилова Е.Р., Цветаева Н.В. М.Е.А. Национальные рекомендации по диагностике и лечениюпроксизмальной ночной гемоглобинурии // Онкогематология. 2014. Vol. 2. P. 20–28.
Kaufman D.W. et al. Relative incidence of agranulocytosis and aplastic anemia // Am. J. Hematol. 2006.
Михайлова Е.А., Фидарова З.Т., и др. Протокол комбинированной иммуносупрессивной терапии больных апластической анемией (редакция 2024г) // Алгоритмы диагностики и протоколы лечения заболеваний системы крови: в двух томах. Под ред. Е.Н. Паровичниковой. Том 1.- М.: Практика, 2024. стр 271-287.
Killick S.B. et al. Guidelines for the diagnosis and management of adult aplastic anaemia. // Br. J. Haematol. England, 2016. Vol. 172, № 2. P. 187–207.
Soulier J. Fanconi anemia. // Hematology Am. Soc. Hematol. Educ. Program. 2011. Vol. 2011. P. 492–497.
Camitta B.M. What is the definition of cure for aplastic anemia? // Acta Haematologica. 2000. Vol. 103, № 1. P. 16–18.
Dokal I. Dyskeratosis congenita. // Hematology. 2011. Vol. 2011. P. 480–486.
Kulasekararaj A, Cavenagh J,Dokal I, Foukaneli T, Gandhi S, Garg M, et al.Guidelines for the diagnosis and management of adultaplastic anaemia: A British Society for HaematologyGuideline. Br J Haematol. 2024;204(3):784–804. https://doi.org/10.1111/bjh.19236
Peslak S.A., Olson T., Babushok D. V. Diagnosis and Treatment of Aplastic Anemia // Current Treatment Options in Oncology. Springer New York LLC, 2017. Vol. 18, № 12.
Пантелеев М.А. et al. Практическая коагулология. 2010. 192 p.
Hayward C.P.M. How I investigate for bleeding disorders // International Journal of Laboratory Hematology. Blackwell Publishing Ltd, 2018. Vol. 40. P. 6–14.
Nielsen P. et al. Iron Stores in Patients with Myelodysplasia and Aplastic Anemia. // Blood. 2006. Vol. 108, № 11. P. 3726–3726.
DeZern A.E., Churpek J.E. Approach to the diagnosis of aplastic anemia // Blood Adv. American Society of Hematology, 2021. Vol. 5, № 12. P. 2660–2671.
Kelsey P. et al. Guidelines for the use of platelet transfusions // Br. J. Haematol. 2003. Vol. 122, № 1. P. 10–23.
Maciejewski J.P., Mufti G.J. Whole genome scanning as a cytogenetic tool in hematologic malignancies // Blood. 2008. Vol. 112, № 4. P. 965–974.
Maciejewski J.P. et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia // Blood. 2002. Vol. 99, № 9. P. 3129–3135.
Gupta V. et al. Clinical relevance of cytogenetic abnormalities at diagnosis of acquired aplastic anaemia in adults // Br. J. Haematol. 2006. Vol. 134, № 1. P. 95–99.
Miano M., Dufour C. The diagnosis and treatment of aplastic anemia: a review // Int. J. Hematol. 2015. Vol. 101, № 6. P. 527–535.
Dumitriu B. et al. Red cells, iron, and erythropoiesis: Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia // Blood. 2015. Vol. 125, № 4. P. 706–709.
Jerez A. et al. STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients // Blood. 2013. Vol. 122, № 14. P. 2453–2459.
Du Y. et al. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload. // Acta Haematol. Switzerland, 2017. Vol. 138, № 2. P. 119–128.
Borowitz M.J. et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry // Cytom. Part B - Clin. Cytom. Wiley-Liss Inc., 2010. Vol. 78, № 4. P. 211–230.
Ogawa S. Clonal hematopoiesis in acquired aplastic anemia // Blood. 2016. Vol. 128, № 3. P. 337–347.
Parker C.J. Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria. // Hematology. United States, 2016. Vol. 2016, № 1. P. 208–216.
Brown K.E. et al. Hepatitis-associated aplastic anemia // N. Engl. J. Med. 1997. Vol. 336, № 15. P. 1059–1064.
Карагюлян С.Р. et al. Технические сложности выполнения спленэктомии при заболеваниях системы крови // Клиническая онкогематология. 2017. Vol. 10, № 1. P. 101–107.
Alter B.P. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. // Hematology. 2007. P. 29–39.
Михайлова Е.А. et al. Клинические рекомендации по диагностике и лечению апластической анемии (редакция 2019 г.) // Гематология и трансфузилогия. 2020. Vol. 65, № 2. P. 208–226.
Smith L.G. Reactions to blood transfusions // Am. J. Nurs. 1984. Vol. 84, № 9. P. 1096–1101.
Scheinberg P. Aplastic anemia: therapeutic updates in immunosuppression and transplantation. // Hematology. 2012. P. 292–300.
Townsley D.M., Winkler T. Nontransplant therapy for bone marrow failure // ASH Educ. Progr. B. 2016. Vol. 2016, № 1. P. 83–89.
Desmond R. et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug // Blood. 2014. Vol. 123, № 12. P. 1818–1825.
Desmond R. et al. Eltrombopag in Aplastic Anemia // Seminars in Hematology. 2015. Vol. 52, № 1. P. 31–37.
Fattizzo B. et al. Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag. // American journal of hematology. United States, 2019.
Lee J.W. et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: A subgroup analysis of 116 patients from the EPIC trial // Blood. 2010. Vol. 116, № 14. P. 2448–2454.
Bacigalupo A. et al. Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy - The European Group for blood and marrow transplantation experience // Semin. Hematol. 2000. Vol. 37, № 1. P. 69–80.
Bacigalupo A. et al. Long‐term follow‐up of severe aplastic anaemia patients treated with antithymocyte globulin // Br. J. Haematol. 1989. Vol. 73, № 1. P. 121–126.
Rosenfeld S. et al. Antithymocyte Globulin and Cyclosporine for Severe Aplastic Anemia: Association between Hematologic Response and Long-term Outcome // J. Am. Med. Assoc. 2003. Vol. 289, № 9. P. 1130–1135.
Михайлова Е.А., Фидарова З.Т., Устинова Е.Н., Троицкая В.В., Гальцева И.В., Шитарева И.В. и др. Комбинированная иммуносупрессивная теарпия у больных апластической анемией: эффективность повторных курсов. // Гематология и трансфузиология. 2014. Vol. 59, № 4. P. 11–18.
Scheinberg P. et al. Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia // Br. J. Haematol. 2009. Vol. 144, № 2. P. 206–216.
Marchiò C., Dowsett M., Reis-Filho J.S. Revisiting the technical validation of tumour biomarker assays: How to open a Pandora’s box // BMC Med. 2011. Vol. 9.
Bacigalupo A. et al. Bone marrow transplantation (BMT) versus immunosuppression for the treatment of severe aplastic anaemia (SAA): A report of the EBMT SAA Working Party // Br. J. Haematol. 1988. Vol. 70, № 2. P. 177–182.
Scheinberg P. et al. Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia // Am. J. Hematol. 2014. Vol. 89, № 5. P. 467–469.
Peffault de Latour R. et al. Nationwide survey on the use of horse antithymocyte globulins (ATGAM) in patients with acquired aplastic anemia: A report on behalf of the French Reference Center for Aplastic Anemia. // Am. J. Hematol. United States, 2018. Vol. 93, № 5. P. 635–642.
Михайлова Е.А. et al. Комбинированная иммуносупрессивная терапия больных апластической анемией: повторные курсы антитимоцитарного глобулина // ГЕМАТОЛОГИЯ И ТРАНСФУЗИОЛОГИЯ. 2014. Vol. 59, № 4. P. 11–18.
Bacigalupo A. How I treat acquired aplastic anemia // Blood. 2017. Vol. 129, № 11. P. 1428–1436.
Scheinberg P., Young N.S. How I treat acquired aplastic anemia. // Blood. 2012. Vol. 120, № 6. P. 1185–1196.
Scheinberg P. et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia // N. Engl. J. Med. 2011. Vol. 365, № 5. P. 430–438.
Gafter-Gvili A. et al. ATG plus cyclosporine reduces all-cause mortality in patients with severe aplastic anemia--systematic review and meta-analysis // Acta Haematol. Acta Haematol, 2008. Vol. 120, № 4. P. 237–243.
Yamazaki H. et al. Cyclosporine Therapy for Acquired Aplastic Anemia: Predictive Factors for the Response and Long-term Prognosis // Int. J. Hematol. 2007 853. Springer, 2007. Vol. 85, № 3. P. 186–190.
Hong Y. et al. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis. // Clin. Drug Investig. 2019. Vol. 39, № 2. P. 141–156.
Olnes M.J. et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. // N. Engl. J. Med. 2012. Vol. 367, № 1. P. 11–19.
Dietz A.C. et al. Evolving Hematopoietic Stem Cell Transplantation Strategies in Severe Aplastic Anemia // Curr. Opin. Pediatr. NIH Public Access, 2016. Vol. 28, № 1. P. 3.
Park Y.B. et al. Incidence and etiology of overt gastrointestinal bleeding in adult patients with aplastic anemia // Dig. Dis. Sci. Dig Dis Sci, 2010. Vol. 55, № 1. P. 73–81.
Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression // Gastroenterology. Gastroenterology, 1990. Vol. 99, № 2. P. 345–351.
Ивашкин В.Т. et al. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Vol. 30, № 1. P. 49–70.
Scally B. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials // Lancet Gastroenterol. Hepatol. Elsevier Ltd, 2018. Vol. 3, № 4. P. 231–241.
Höchsmann B. et al. Supportive care in severe and very severe aplastic anemia // Bone Marrow Transplantation. 2013. Vol. 48, № 2. P. 168–173.
Fan E., Brodie D., Slutsky A.S. Acute respiratory distress syndrome advances in diagnosis and treatment // JAMA - Journal of the American Medical Association. American Medical Association, 2018. Vol. 319, № 7. P. 698–710.
Young P. et al. Effect of a buffered crystalloid solution vs saline on acute kidney injury among patients in the intensive care unit: The SPLIT randomized clinical trial // JAMA - J. Am. Med. Assoc. American Medical Association, 2015. Vol. 314, № 16. P. 1701–1710.
Hoorn E.J. Intravenous fluids: balancing solutions // Journal of Nephrology. Springer New York LLC, 2017. Vol. 30, № 4. P. 485–492.
Arends J. et al. ESPEN guidelines on nutrition in cancer patients // Clin. Nutr. Churchill Livingstone, 2017. Vol. 36, № 1. P. 11–48.
Шихмирзаев Т.А. et al. Фармакопрофилактика трансфузионных реакций // Вестник Национального медико-хирургического Центра им. Н. И. Пирогова. 2018. Vol. 13, № 2. P. 95–99.
Аксельрод Б.А. et al. Клиническое использование эритроцитсодержащих компонентов донорской крови // Гематология и трансфузиология. 2018. Vol. 63, № 4. P. 372–435.
Криволапов Ю.А. Технические аспекты выполнения трепанобиопсий костного мозга. Клиническая онкогематология 2014; 7:290—295 // Клиническая онкогематология. 2014. Vol. 7. P. 290–295.
Wang J. et al. Diagnostic utility of bilateral bone marrow examination: Significance of morphologic and ancillary technique study in malignancy // Cancer. Cancer, 2002. Vol. 94, № 5. P. 1522–1531.
SPIRIN M., GALSTYAN G., DROKOV M. Central venous access in lymphoma patients (pts) with superior vena cava syndrome (SVCS) // INTENSIVE CARE Med. Exp. 2019. Vol. 7, № Suppl. 3:001341. P. 388–389.
Pluschnig U. et al. Extravasation emergencies: state-of-the-art management and progress in clinical research. // Memo. Springer, 2016. Vol. 9, № 4. P. 226–230.
Zeidler K. et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. // Transfusion. 2011. Vol. 51, № 11. P. 2269–2276.
Zerati A.E. et al. Totally implantable venous catheters : history , implantation technique and complications. // J Vasc Bras. 2017. Vol. 16, № 2. P. 128–139.
Gow K.W., Tapper D., Hickman R.O. Between the lines: The 50th anniversary of long-term central venous catheters // Am. J. Surg. Elsevier Ltd, 2017. Vol. 213, № 5. P. 837–848.
Yeral M. et al. Tunnelled central venous catheter-related problems in the early phase of haematopoietic stem cell transplantation and effects on transplant outcome. // Turkish J. Haematol. Off. J. Turkish Soc. Haematol. Galenos Yayinevi, 2015. Vol. 32, № 1. P. 51–57.
Maki D.G., Kluger D.M., Crnich C.J. The Risk of Bloodstream Infection in Adults With Different Intravascular Devices: A Systematic Review of 200 Published Prospective Studies // Mayo Clin. Proc. Elsevier, 2006. Vol. 81, № 9. P. 1159–1171.
Hamilton H. Central Venous Catheters / ed. Bodenham A.R. Oxford, UK: Wiley-Blackwell, 2009.
Biffi R. Introduction and Overview of PICC History // Peripherally Inserted Central Venous Catheters. Milano: Springer Milan, 2014. P. 1–6.
Linenberger M.L. Catheter-related thrombosis: risks, diagnosis, and management. // J. Natl. Compr. Canc. Netw. 2006. Vol. 4, № 9. P. 889–901.
Lee A.Y.Y., Kamphuisen P.W. Epidemiology and prevention of catheter-related thrombosis in patients with cancer // J. Thromb. Haemost. 2012. № 10. P. 1491–1499.
Цепенщинков Л.., Лядов В.К. Периферически имплантируемый центральный венозный катетер: обзор литераутры. // Клиническая онкогематология. 2014. Vol. 7, № 2. P. 220–228.
Linder L.E. et al. Material thrombogenicity in central venous catheterization: a comparison between soft, antebrachial catheters of silicone elastomer and polyurethane. // JPEN. J. Parenter. Enteral Nutr. 1984. Vol. 8, № 4. P. 399–406.
Watters V.A., Grant J.P. Use of Electrocardiogram to Position Right Atrial Catheters During Surgery // Ann. Surg. Vol. 225, № 2. P. 165–171.
Taal M.W., Chesterton L.J., McIntyre C.W. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis // Nephrol. Dial. Transplant. Oxford University Press, 2004. Vol. 19, № 6. P. 1542–1545.
Lobato E.B. et al. Cross-sectional area of the right and left internal jugular veins. // J. Cardiothorac. Vasc. Anesth. 1999. Vol. 13, № 2. P. 136–138.
Червонцева А.М. Повреждение сосудистого эндотелия в процессе лечения острых миелоидных лейкозов. 2008.
Багирова Н.С. Инфекции, связанные с внутрисосудистыми устройствами: терминология, диагностика, профилактика и терапия // Злокачественные опухоли. 2014. № 3. P. 164–171.
Bannon M.P., Heller S.F., Rivera M. Anatomic considerations for central venous cannulation. // Risk Manag. Healthc. Policy. Dove Press, 2011. Vol. 4. P. 27–39.
Milling T.J. et al. Randomized, controlled clinical trial of point-of-care limited ultrasonography assistance of central venous cannulation: The Third Sonography Outcomes Assessment Program (SOAP-3) Trial* // Crit. Care Med. 2005. Vol. 33, № 8. P. 1764–1769.
Зозуля Н.И., Кумскова М.А. Протокол диагностики и лечения гемофилии. // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Том 1. Практика / ed. Савченко В.Г. Москва, 2018. P. 333–358.
Галстян Г.М. НАРУШЕНИЯ ГЕМОСТАЗА, ОБУСЛОВЛЕННЫЕ ДЕФИЦИТОМ ВИТАМИН К-ЗАВИСИМЫХ ФАКТОРОВ СВЕРТЫВАНИЯ КРОВИ — ПАТОГЕНЕЗ, СПОСОБЫ КОРРЕКЦИИ И РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ. // Гематология и трансфузиология. 2012. Vol. 27, № 2. P. 7–21.
Habermalz B. et al. Laparoscopic splenectomy: The clinical practice guidelines of the European Association for Endoscopic Surgery (EAES) // Surgical Endoscopy and Other Interventional Techniques. Surg Endosc, 2008. Vol. 22, № 4. P. 821–848.
Воробьев А.И. et al. Критические состояния при гемобластозах (типичные формы и выживаемость в условиях отделения реанимации). // Терапевтический архив. 1993. Vol. 65, № 7. P. 3–6.
Галстян Г.М., Городецкий В.М. Опыт работы отделения реанимации и интенсивной терапии ФГБУ ГНЦ МЗиСР РФ // Клиническая онкогематология. 2011. Vol. 4, № 1. P. 75–78.
Lamia B. et al. Changes in severity and organ failure scores as prognostic factors in onco-hematological malignancy patients admitted to the ICU // Intensive Care Med. Intensive Care Med, 2006. Vol. 32, № 10. P. 1560–1568.
Evison J.M. et al. Intensive care unit admission in patients with haematological disease: incidence, outcome and prognostic factors. 2001.
Silfvast T. et al. Multiple organ failure and outcome of critically ill patients with haematological malignancy // Acta Anaesthesiol. Scand. Acta Anaesthesiol Scand, 2003. Vol. 47, № 3. P. 301–306.
Benoit D.D. et al. Outcome and early prognostic indicators in patients with a hematologic malignancy admitted to the intensive care unit for a life-threatening complication // Crit. Care Med. Crit Care Med, 2003. Vol. 31, № 1. P. 104–112.
Schellongowski P. et al. Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experience // Haematologica. 2011. Vol. 96, № 2. P. 231–237.
Medić M.G. et al. Hematologic malignancies in the medical intensive care unit – Outcomes and prognostic factors // Hematology. Maney Publishing, 2015. Vol. 20, № 5. P. 247–253.
Jackson K. et al. Outcomes and prognostic factors for patients with acute myeloid leukemia admitted to the intensive care unit // Leuk. Lymphoma. Leuk Lymphoma, 2013. Vol. 55, № April. P. 1–8.
Ahmed T. et al. Outcomes and changes in code status of patients with acute myeloid leukemia undergoing induction chemotherapy who were transferred to the intensive care unit // Leuk. Res. Elsevier Ltd, 2017. Vol. 62. P. 51–55.
Протоколы трансплантации аллогенных гепомоэтических стволовых клеток. Под ред. В.Г. Савченко. М.: Практика, 2020. 320 p.
Willis L. et al. Recent developments in drug therapy for aplastic anemia // Ann. Pharmacother. Ann Pharmacother, 2014. Vol. 48, № 11. P. 1469–1478.
Bonfim C. et al. Bone Marrow Transplantation (BMT) for heavily Transfused Patients (pts) with Severe Aplastic Anemia (SAA): 147 pts treated at the same institution with Busulfan (BU) + Cyclophosphamide (CY) // Biol. Blood Marrow Transplant. Elsevier, 2006. Vol. 12, № 2. P. 28.
de Latour R.P., Risitano A.M., Dufour C. Severe Aplastic Anemia and PNH // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 579–587.
Michonneau D., Socié G. GVHD Prophylaxis (Immunosuppression) // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 177–183.
Nagler A., Shimoni A. Conditioning // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 7th ed. / ed. Carreras E. et al. Springer, 2019. P. 99–109.
Baron F. et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation // Haematologica. 2017. Vol. 102, № 2.
Basak G.W. Gastrointestinal Complications // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 2019. P. 381–386.
Chaturvedi S., George B., Savani B.N. Bleeding and Thrombotic Complications // The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. 2019. P. 301–306.
Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, № 6. P. 649–655.
Gratwohl A. The EBMT risk score // Bone Marrow Transplantation. Nature Publishing Group, 2012. Vol. 47, № 6. P. 749–756.
Sorror M.L. et al. Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study // Biol. Blood Marrow Transplant. Elsevier Inc., 2015. Vol. 21, № 8. P. 1479–1487.
Сопроводительная терапия при лечении заболеваний системы крови. Практическое руководство / под ред. Е. Н. Паровичниковой, Г. М. Галстяна. М.: Практика, 2024. 512 с.
Трансплантация аллогенных гемопоэтических стволовых клеток. Практическое руководство . Под ред. Е.Н.Паровичниковой, Т.В.Гапоновой, М.Ю.Дрокова. - М.: Практика, 2024. - 640 с.
Дроков М.Ю, Моисеев И.С., Олейник Ю.А . Эффективность и безопасность метода трансплантации аллогенных гемопоэтических стволовых клеток и костного мозга у взрослых пациентов с заболеваниями системы крови: опрос экспертов трансплантационных центров Российской Федерации, CTT JOURNAL, March (13) c49-92
Scheinberg P, Rios O, Scheinberg P, Weinstein B, Wu CO, YoungNS. Prolonged cyclosporine administration after antithymocyteglobulin delays but does not prevent relapse in severe aplastic anemia. Am J Hematol. 2014;89(6):571–4.
Peffault de Latour R, Kulasekararaj A, Iacobelli S, Terwel SR, CookR, Griffin M, et al. Eltrombopag added to immunosuppression insevere aplastic anemia. N Engl J Med. 2022;386(1):11–23